Progresses in Developing Novel Targets ADCs of HDM’s XDC Technology & Its Clinical Focus on Solid Tumors With Enhanced Efficiency & Therapeutic Index
- Highlighting the strategy of HDM on the new generation of ADCs/XDCs, including novel targets, dual-payload, and sitespecific conjugation
- Discussing the preclinical and therapeutic implications of inhouse discovered novel payloads in widening the therapeutic window and conquering drug resistance
- Updating the preclinical and clinical data demonstrating enhanced potency, safety, and tumor-selective efficacy for HDM 2005, HDM 2012, and HDM2020